Market Closed - Nasdaq Stockholm 07:59:43 2023-11-03 am EDT 5-day change 1st Jan Change
0.1604 SEK -1.11% Intraday chart for IRRAS AB -.--% -.--%
Sales 2023 * 165M 15.91M Sales 2024 * 249M 23.96M Capitalization 182M 17.52M
Net income 2023 * -101M -9.74M Net income 2024 * -29M -2.8M EV / Sales 2023 * 2.38 x
Net Debt 2023 * 211M 20.31M Net Debt 2024 * 258M 24.85M EV / Sales 2024 * 1.77 x
P/E ratio 2023 *
-0.13 x
P/E ratio 2024 *
-0.43 x
Employees 47
Yield 2023 *
-
Yield 2024 *
-
Free-Float 3.55%
More Fundamentals * Assessed data
Dynamic Chart
1 year
0.11
Extreme 0.1125
0.22
3 years
0.11
Extreme 0.1125
5.50
5 years
0.11
Extreme 0.1125
31.20
10 years
0.11
Extreme 0.1125
47.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 17-12-31
Director of Finance/CFO 38 -
Director/Board Member 66 15-05-31
Members of the board TitleAgeSince
Chairman 51 11-12-31
Director/Board Member 66 15-05-31
Director/Board Member 69 17-08-31
More insiders
Irras AB is a Sweden-based medical technology company. It offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company’s shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise